ChromeOS

Elsevier and Iktos Partner to Deliver an AI-Driven Synthetic Chemistry Platform for Drug Discovery

Retrieved on: 
Tuesday, March 5, 2024

Combining the world's largest chemistry database, Reaxys from Elsevier, with cutting-edge AI from Iktos, the advanced platform will enable pharmaceutical companies to identify preclinical drug candidates faster

Key Points: 
  • The partnership will strengthen Elsevier's flagship chemistry solution, Reaxys , by combining the company's high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
  • We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help reshape the landscape of small molecule discovery."
  • Yann Gaston-Mathé, CEO, Iktos said: "Data is the foundation of AI, and we are very excited to partner with Elsevier.
  • The new predictive retrosynthesis and synthetic accessibility tools are based on Iktos' proprietary retrosynthetic technology and trained on Reaxys' reaction database.

Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report

Retrieved on: 
Tuesday, February 27, 2024

(read the full article here)

Key Points: 
  • (read the full article here)
    Avance Clinical CEO, Yvonne Lungershausen was interviewed by SCRIP Intelligence about the current biotech financial and drug development climate in the US and signs of growth.
  • Investors are really being super cautious about where they're investing and relatively, there's not a high-risk appetite," Lungershausen said to SCRIP in the interview.
  • SCRIP Intelligence noted that Avance Clinical presented at JPM and Biotech Showcase a new analysis by market research leader, Frost & Sullivan on the biotech sector and the challenges they have finding the right fit or size CRO (See report here).
  • For more information about the benefits of running your next study with Avance Clinical contact us: [email protected]

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Retrieved on: 
Wednesday, March 6, 2024

Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

Key Points: 
  • Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
  • The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.
  • The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
  • The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology.

CB Insights Ranks Verana Health as a Leader in EHR-based Patient Recruitment Market

Retrieved on: 
Wednesday, March 6, 2024

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data, announced that CB Insights ranked Verana Health as a Leader in the EHR-based patient recruitment market.

Key Points: 
  • SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data, announced that CB Insights ranked Verana Health as a Leader in the EHR-based patient recruitment market.
  • This market is dedicated to leveraging electronic health record (EHR) data to amplify the efficiency and effectiveness of identifying eligible patients for clinical trials.
  • “This ranking from CB Insights underscores our team’s commitment to delivering innovative solutions that can help improve patient outcomes,” said Verana Health CEO Sujay Jadhav.
  • Last year, Verana Health also launched multiple Qdata ® modules across the three therapeutic areas of ophthalmology, neurology, and urology.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Getting Healthcare Innovations to Patients Faster with the Proven Kymanox Hyper-Virtual Model™

Retrieved on: 
Tuesday, February 27, 2024

Called the Kymanox Hyper-Virtual Model™, the innovative strategy empowers businesses to expedite the development of commercial-ready solutions more efficiently.

Key Points: 
  • Called the Kymanox Hyper-Virtual Model™, the innovative strategy empowers businesses to expedite the development of commercial-ready solutions more efficiently.
  • Now, the Kymanox Hyper-Virtual Model™ can be offered to a wider network of clients and the venture capital investors who back them.
  • This innovative approach will help more life science companies get healthcare innovations to patients faster.
  • While Perry welcomes conversations with organizations who are interested in working with Kymanox, he also invites organizations to use the Hyper-Virtual Model™ without Kymanox.

United States and European Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

The "Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024" report has been added to ResearchAndMarkets.com's offering.
  • This landmark report includes 300 patients involved in 1-2 clinical trials within the last 2 years from the United States and Europe.
  • It explores experiences with consent and onboarding (including randomization), along with preferences, areas of satisfaction, and potential future changes regarding patient diaries.
  • These diaries are critical to clinical trials as they capture data pertaining to Patient Reported Outcomes (PROs), including patient experience, symptoms, and adverse effects.

Impact of the In-Vitro Diagnostic Regulation (IVDR) on the Conduct of Clinical Trials in the EU and CRO Outsourcing - 2024 Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024

The "Impact of the InVitro Diagnostic Regulation (IVDR) on the Conduct of Clinical Trials in the EU and CRO Outsourcing - 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Impact of the InVitro Diagnostic Regulation (IVDR) on the Conduct of Clinical Trials in the EU and CRO Outsourcing - 2024" report has been added to ResearchAndMarkets.com's offering.
  • In Vitro Diagnostic (IVD) tests are critical to clinical trial operations, serving to help select patients in clinical trials, provide accurate efficacy results, monitor patient response, and more.
  • As a result, current and pending drug clinical trials utilizing IVD tests now must also adhere to the IVDR.
  • However, this process is currently complex and uncoordinated, resulting in delays in clinical trials and patients waiting longer to participate in clinical trials, or even not participating at all.

Aiosyn Launches Kidney Image Analysis Services Through Its NephroPath Platform to Accelerate Drug Development Studies

Retrieved on: 
Thursday, February 29, 2024

Aiosyn , a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform .

Key Points: 
  • Aiosyn , a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform .
  • By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services .
  • Through Nephropath’s Kidney Image Analysis Services, Aiosyn offers whole kidney quantification and custom kidney analyses.
  • “Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.

Greenphire Adds Industry Veteran Dan Shannon as New Chief Experience Officer

Retrieved on: 
Monday, February 26, 2024

Greenphire , a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, today announced the addition of healthcare technology executive Dan Shannon as its new Chief Experience Officer (CXO).

Key Points: 
  • Greenphire , a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, today announced the addition of healthcare technology executive Dan Shannon as its new Chief Experience Officer (CXO).
  • View the full release here: https://www.businesswire.com/news/home/20240226687875/en/
    Dan Shannon joins Greenphire as Chief Experience Officer.
  • Company culture and a compelling product set solidified why I wanted to join Greenphire as my next professional endeavor,” Dan said.
  • “I look forward to helping solve challenging problems for our industry and make a bigger impact through optimizing the company’s customer experience.”